Avanir Pharmaceuticals Announces Filing of IND for AVP-923 for the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis

Avanir Pharmaceuticals, Inc. AVNR today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis. The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.